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Protocol
AbstrACt
Introduction Knee and hip osteoarthritis (OA) is a leading 
cause of disability worldwide. Therapeutic exercise is a 
recommended core treatment for people with knee and hip 
OA, however, the observed effect sizes for reducing pain and 
improving physical function are small to moderate. This may 
be due to insufficient targeting of exercise to subgroups of 
people who are most likely to respond and/or suboptimal 
content of exercise programmes. This study aims to identify: 
(1) subgroups of people with knee and hip OA that do/
do not respond to therapeutic exercise and to different types 
of exercise and (2) mediators of the effect of therapeutic 
exercise for reducing pain and improving physical function. 
This will enable optimal targeting and refining the content of 
future exercise  
interventions.
Methods and analysis Systematic review and individual 
participant data meta-analyses. A previous comprehensive 
systematic review will be updated to identify randomised 
controlled trials that compare the effects of therapeutic 
exercise for people with knee and hip OA on pain and 
physical function to a non-exercise control. Lead authors of 
eligible trials will be invited to share individual participant 
data. Trial-level and participant-level characteristics (for 
baseline variables and outcomes) of included studies will be 
summarised. Meta-analyses will use a two-stage approach, 
where effect estimates are obtained for each trial and then 
synthesised using a random effects model (to account for 
heterogeneity). All analyses will be on an intention-to-treat 
principle and all summary meta-analysis estimates will be 
reported as standardised mean differences with  
95% CI.
Ethics and dissemination Research ethical or governance 
approval is exempt as no new data are being collected and no 
identifiable participant information will be shared. Findings will 
be disseminated via national and international conferences, 
publication in peer-reviewed journals and summaries posted 
on websites accessed by the public and clinicians.
PrOsPErO registration number CRD42017054049.
strength and limitation of this study
 ► This will be the first study in the field of therapeutic 
exercise and osteoarthritis to combine individual 
participant data from existing randomised controlled 
trials.
 ► Combining individual participant data from existing 
trials will increase the power to identify who benefits 
most from therapeutic exercise, and to identify 
underlying mechanisms of action.
 ► Individual participant data meta-analyses facilitates 
standardised analyses across studies, allows direct 
derivation of desired information independent of 
significance or reporting, enables subgroup effects 
and interactions (differences in effects between 
subgroups) to be examined, and may provide more 
outcomes than were considered in a single original 
publication.
 ► A disadvantage to completing individual participant 
data meta-analyses is the time required to complete 
them, including obtaining, checking and combining 
the data.
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IntrOduCtIOn 
Osteoarthritis (OA) can be defined as a clinical syndrome 
of joint pain accompanied by varying degrees of func-
tional limitation and reduced quality of life.1 OA, partic-
ularly of the knee and hip, is one of the leading causes 
of disability worldwide, with an estimated global age-stan-
dardised prevalence of 3.8% (95% CI 3.6% to 4.1%) for 
knee OA and 0.85% (95% CI 0.74% to 1.02%) for hip 
OA.2 The burden of OA will increase as the population 
ages and the prevalence of obesity rises.2 3 
No cure currently exists for OA and as such treatment 
strategies aim to reduce pain and improve physical func-
tion, and enhance quality of life.4 Clinical guidelines, 
including the National Institute for Health and Care 
Excellence OA guidelines,1 consistently recommend ther-
apeutic exercise as a core treatment for people with knee 
and hip OA.5 6 Therapeutic exercise involves participa-
tion in physical activity that is planned, structured, repeti-
tive and purposeful for the improvement or maintenance 
of a specific health condition such as OA.7 It encom-
passes general aerobic exercise, strengthening, flexibility, 
balance or body-region specific exercises.7 Although both 
general (aerobic) exercise and strengthening exercise are 
recommended for people with knee and hip OA, limited 
information is available on the optimal prescription of 
therapeutic exercise (eg, the optimal type, dose, inten-
sity and setting of exercise and how best to progress exer-
cise).1 Numerous systematic reviews and meta-analyses 
support the role of therapeutic exercise for knee and hip 
OA, consistently demonstrating that it can reduce pain 
and improve physical function.8–10 However, results from 
randomised controlled trials (RCTs) show the observed 
effect sizes from exercise interventions are small to 
moderate, can decline over time, and only approximately 
50% of participants achieve a clinically important treat-
ment response.11–13 The modest average benefits obtained 
from therapeutic exercise could be due to the inclusion 
of subgroups of people who are unlikely to benefit from 
exercise, and thus the overall effect is closer to the null 
than if the trial had been solely undertaken in those that 
are likely to benefit.4 Better targeting of exercise treat-
ments for people with knee and hip OA could potentially 
lead to improved treatment effects and patient outcomes, 
as well as more efficient use of healthcare services, in a 
similar way as demonstrated for low back pain.14 15 Such 
an approach requires the identification of subgroups who 
are likely to respond better to therapeutic exercise than 
others.
Little previous research has examined whether 
outcomes from exercise for OA vary for subgroups of 
people defined by individual-level characteristics (treat-
ment effect moderators).16 Exploratory secondary 
analyses of some RCTs suggest a range of potential 
moderators of the effects of exercise, including age,17 
sex,18 obesity,19 pain severity and duration,17 18 functional 
ability,18 strength,20 21 knee malalignment,19 20 severity of 
joint damage,22 anxiety and depression18 and treatment 
outcome expectations.23 However, post hoc analyses 
have low statistical power to detect significant subgroup 
effects, and are at high risk of yielding spurious findings 
due to multiple testing.24Although these exploratory 
subgroup analyses are inconclusive, they add credence 
to the hypothesis that not all people with knee and hip 
OA respond similarly to exercise, with variability in effects 
related to individual-level characteristics.
Modest average benefits of therapeutic exercise in 
people with knee and hip OA may additionally be 
explained by suboptimal content of exercise programmes. 
Systematic reviews have identified various characteristics 
of exercise programmes that appear to be associated 
with larger effects, but with conflicting results.10 25 Treat-
ment mediators (causal links between treatment and 
outcome16) of therapeutic exercise on OA symptoms 
are largely unknown, making it difficult to design thera-
peutic exercise programmes for optimal effects on symp-
toms. If true mediators were identified and targeted, the 
positive effects of therapeutic exercise may be improved. 
Increased muscle strength, decreased extension deficits 
and improved proprioception have been identified as 
potential working mechanisms for the positive effect of 
therapeutic exercise for knee OA, and increased muscle 
strength for hip OA.26 However, meta-analyses at the 
study-level (using aggregated study results)26 have been 
prone to study-level confounding regarding the identifi-
cation of individual-level effects.25 26
The investigation of individual response to exercise 
treatment, and the identification of factors that may 
cause differential response to such treatment or to partic-
ular components of exercise therapy, requires individu-
al-level data analysis. To our knowledge, this type of trial 
data pooling and analysis has not yet been completed 
in the field of therapeutic exercise and OA. Although 
several systematic reviews are available,8–10 none use indi-
vidual participant data (IPD). Given there are now over 
60 RCTs of exercise for knee and hip OA,10 it is timely to 
combine IPD from these existing trials. This will increase 
the power to identify who benefits most from thera-
peutic exercise, and to identify underlying mechanisms 
of action.27 IPD meta-analysis facilitates standardised 
analyses across studies, allows direct derivation of desired 
information independent of significance or reporting, 
enables subgroup effects and interactions (differences 
in effects between subgroups) to be examined, and may 
provide longer follow-up, more participants and more 
outcomes than were considered in the original publica-
tion.27 Therefore, IPD meta-analyses are potentially more 
reliable than traditional aggregate data meta-analyses for 
the identification of treatment effect moderators, may 
lead to different conclusions and may produce more clin-
ically relevant results.27
AIM
To identify (1) subgroups of people with knee and hip 
OA that respond/do not respond to therapeutic exercise 
and to different types of exercise (effect moderators) and 
group.bmj.com on January 23, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
 3Holden MA, et al. BMJ Open 2017;7:e018971. doi:10.1136/bmjopen-2017-018971
Open Access
(2) mediators of the effect of therapeutic exercise for 
reducing pain and improving physical function to facili-
tate better targeting of future exercise interventions and 
refine exercise programme content.
specific analytic objectives
1. Determine the short-term (12 weeks), medium-term 
(6 months) and long-term (1 year) overall effects of 
therapeutic exercise on pain and physical function 
for people with knee and hip OA compared with a 
non-exercise control.
2. Determine which study-level characteristics of thera-
peutic exercise interventions are associated with im-
proved overall effects on pain and physical function 
in people with knee and hip OA, including the type, 
intensity, duration, setting and deliverer of exercise.
3. Identify individual-level characteristics of people with 
knee and hip OA that are associated with the short-
term, medium-term and long-term effects of thera-
peutic exercise on pain and physical function.
4. Identify individual-level characteristics of people with 
knee and hip OA that are associated with the effects 
of different characteristics of therapeutic exercise in-
terventions; including the type, intensity, duration, 
setting and deliverer of exercise.
5. Investigate the effect estimates for objectives 1–4 in 
subgroups of people with only knee OA and only hip 
OA to examine whether they differ by joint site.
6. Evaluate the mediating effects of muscle strength (for 
people with knee and hip OA), proprioception (for 
people with knee OA) and extension deficits (for peo-
ple with knee OA) in the association between thera-
peutic exercise and pain and physical function. The 
effects of individual and combined mediators will be 
explored.
MEthOds And AnAlysIs
We will update a previous systematic review10 to iden-
tify relevant RCTs and after agreement from trial leads, 
undertake an IPD meta-analysis. Our systematic review 
and meta-analysis will be completed in accordance with 
methods advocated by the Cochrane IPD meta-anal-
ysis group,28 29 and reported according to Preferred 
Reporting Items for Systematic Reviews and Meta-Anal-
yses (PRISMA)-IPD guidance.30 Five members of the 
Research User Group at the Research Institute of 
Primary Care and Health Sciences, Keele University, have 
formed a Patient and Public Involvement and Engage-
ment (PPIE) working group for this study. In line with 
INVOLVE31 there will be PPIE involvement at every stage 
of the project. We will work in collaboration with the OA 
Trial Bank (www. oatrialbank. com), an initiative estab-
lished in 2010 to collect and analyse IPD of published 
RCTs in OA.32 33 The final IPD database will be deposited 
with the OA Trial Bank for the benefit of the wider OA 
research community.
Phase 1: trial identification
We previously conducted a systematic review that iden-
tified 60 RCTs of exercise interventions for people with 
knee and hip OA that are relevant for inclusion within 
this study.10 We will update this review. The search 
strategy previously developed will be re-run from the date 
of the previous search (March 2012) in the following elec-
tronic databases: Medline, EMBASE, Cumulative Index 
to Nursing and Allied Health Literature, Association 
for Management Education and Development, Health 
Management Information Consortium, Cochrane Data-
base of Systematic Reviews, Cochrane Controlled Clin-
ical Trials, Database of Reviews of Effectiveness, National 
Health Service Economic Evaluations Database and Web 
of Science. Bibliographies of relevant review articles and 
included articles will be examined for additional poten-
tially relevant trials. There will be no language restriction. 
Full search strategies for Medline and Embase are shown 
in online supplementary appendix 1.
Study selection
Full details of the study selection criteria are listed in 
table 1. In summary, we will evaluate RCTs against the 
following inclusion criteria.
Study population
Adults aged ≥45 years with knee or hip OA; intervention: 
any land-based or water-based therapeutic exercise inter-
vention regardless of content, duration, frequency or 
intensity; comparator: other forms of exercise or no exer-
cise control group;
Outcome measure
At least one measure of self-reported pain or physical 
function;
Study design
RCTs. Trials will be excluded if they concern preopera-
tive or postoperative therapeutic exercise, when exer-
cise is combined with interventions other than advice/
education/self-management/motivational techniques 
(meaning treatment effects cannot clearly be attributed to 
the exercise), or if intervention groups receive identical 
therapeutic exercise interventions. Titles and abstracts 
of identified studies and subsequently full papers will be 
independently reviewed by two reviewers. A third reviewer 
will be consulted to resolve disagreements, if necessary.
Extraction of aggregate data
For each included trial, details on design, sample size, 
population characteristics (knee OA, hip OA or mixed), 
interventions (type, duration and exercise deliverer), 
comparator, candidate baseline variables (potential treat-
ment moderators and mediators) and outcome assessment 
(type of outcome measure and length of follow-up) will 
be extracted and summarised into tables. Two reviewers 
will independently extract outcome data on self-report 
pain and/or physical function at time points nearest to 
12 weeks, 6 months and 12 months postrandomisation. 
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Two reviewers will independently classify the exercise 
interventions of included trials, based on the following a 
priori defined characteristics:
Frequency of exercise: number of exercise sessions per 
week.
Intensity of exercise: low, moderate or high intensity 
(based on published information regarding target heart 
rate (<50% of maximum heart rate (MHR)=low inten-
sity, 50%–70% MHR=moderate intensity, >70%–
85% MHR=high intensity) or metabolic equivalent (MET) 
score (where heart rate information is unavailable) (MET 
score of <3= low intensity, MET 3–6=moderate intensity, 
MET >6=high intensity34 35 ; low or high impact (catego-
rised based on the likely amount of compressive load and 
whether both feet were intermittently off the ground. 
For example, cycling, swimming and walking=low impact; 
jogging, running and jumping=high impact).35
Type of exercise: predominantly strengthening (eg, quad-
riceps strengthening); predominantly general (aerobic) 
(eg, walking and swimming); predominantly mind–
body (eg, yoga and tai-chi)36 ; mixed. As many trials are 
likely to include predominantly strengthening, we will 
classify subsets of predominantly non-weightbearing/
open kinetic chain strengthening exercise versus predom-
inantly weightbearing/closed kinetic chain strengthening 
exercise.
Duration of exercise programme: short (less than 6 weeks) 
or longer durations of up to 12 weeks, and over 12 weeks; 
Table 1 Inclusion/exclusion criteria
Inclusion criteria Exclusion criteria
Population  ► Knee and/or hip pain in adults aged 
≥45 years (mean age >45 years)
 ► Knee and/or hip OA diagnosed by X-ray
 ► Knee and/or hip OA diagnosed according to 
clinical criteria
 ► Knee and/or hip OA diagnosed by 
healthcare professional
 ► Self-reported knee and/or hip OA
 
NB: If population is mixed (eg, OA and RA, 
include if over 50% of participants have OA
 ► Knee and/or hip pain attributable to conditions other than OA
 ► Non-musculoskeletal conditions
 ► RA/other defined inflammatory rheumatological problems
 ► Preoperative patients (people on waiting-lists for knee/hip 
surgery, including total joint replacement)
 ► Postoperative patients (immediately following knee/hip surgery, 
including total joint replacement)
 ► People with ‘patellofemoral pain syndrome’ (overall a different 
problem to ‘OA’)
 ► Animal-based studies
 ► Studies of children
Intervention  ► Any therapeutic exercise intervention (land 
or water based), regardless of content, 
duration, frequency or intensity
 ► Non-exercise interventions
 ► Advice only to exercise or increase physical activity, including 
within wider OA self-management programmes
 ► Exercise or physical activity that was not specifically applied to 
improve OA symptoms and function
 ► Exercise combined with treatment modalities other than 
advice/education/self-management/motivational techniques)
 ► Preoperative/postoperative exercise therapy, that is, exercise 
immediately before, or following knee/hip surgery
Comparator  ► Other forms of exercise (ie, different type, 
duration, frequency or intensity of exercise 
if sufficiently different from the intervention 
arm)
 ► No exercise control group (including usual 
care, waiting list, placebo, attention control 
or no treatment)
 ► Sham treatment (eg, sham ultrasound)
 ► If intervention groups receive identical therapeutic exercise 
interventions (ie, no contrast existing between the intervention 
groups)
 ► If the comparator is a different intervention other than usual 
care, waiting list, placebo, attention control or no treatment (eg, 
manual therapy, ultrasound, intra-articular injection, opioids, 
weight loss, etc) 
Outcome 
measure
 ► Any self-reported measure of pain and/or 
physical function




 ► Quasi-RCT (where the method of allocation 
is known, but is not considered strictly 
random, eg, alternation, date of birth and 
medical record number)
 ► Non-RCT study design
 ► Other study designs for example, surveys, observational 
studies, pre-experiments and postexperiments (without a 
control group), qualitative studies
 ► Systematic reviews
 ► RCT protocols
OA, osteo arthritis; RA, rheumatoid arthritis; RCT, randomised controlled trial.
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total number of exercise sessions; booster sessions or no 
booster sessions.
Setting of exercise: group, individual or mixed; super-
vised in clinic, completed at home or mixed; face-to-face, 
remote exercise instruction or mixed.
Exercise deliverer: healthcare professionals, exercise 
specialists, peer or lay-led or mixed.
Phase 2: collection, checking and standardising individual 
participant data
In collaboration with, and following the procedures of, 
the OA Trial Bank, we will contact lead authors of iden-
tified trials to inform them about the study and invite 
them to share IPD. If the updated systematic review 
yields a large additional number of RCTs suitable for 
inclusion, and many authors are willing to share IPD, 
we may examine the likely power of the IPD meta-anal-
ysis accordingly to the trials promising their IPD using 
a simulation-based approach.37 The collection, cleaning 
and harmonisation of IPD is often resource inten-
sive,28 38 and therefore the power calculation will inform 
how much IPD is required in order to obtain sufficient 
power (eg, 80%) to evaluate our key objectives. If IPD 
is ultimately sought from a subset of studies, this will be 
based on study quality, sample size and improvement to 
power, and independent of effect size to avoid selection 
bias.39
Once a data sharing agreement is in situ, datasets will be 
accepted in any form, provided all data are anonymised 
and variables and categories are adequately labelled in 
English. To ensure accurate pooling of data, each dataset 
will be converted to a common format and variables 
renamed in a consistent manner.
Variables of interest




Age, sex, comorbidities, frailty, fatigue/vitality, quality 
of life, body mass index, baseline physical activity level, 
previous lower limb injury, work status (working yes/
no), manual versus non-manual work, previous physical 
load, family history of OA, socioeconomic status (educa-
tion), social support, currently receiving other treatment, 
smoking status, motivation to exercise and previous knee 
injury/trauma.
Psychological factors
Anxiety/depression, self-efficacy, outcome expectations. 
Disease characteristics: pain location, pain elsewhere, 
pain severity, pain duration, central pain sensitisation, 
pain bothersomeness, physical function, stage of OA 
(early vs established OA40), radiographic joint structure, 
evidence of synovitis and bone marrow lesions from MRIs 
and patellofemoral OA damage.
Biomechanical factors
Proprioception, static/dynamic alignment, strength of 
hip and lower limb musculature, range of movement, leg 
length discrepancy and developmental hip abnormalities/
deformities.
Outcome measures
All self-report pain and physical function outcome data 
at time-points nearest to 12 weeks (short-term), 6 months 
(mid-term) and 1 year (long-term) postrandomisation. If 
more than one measure of self-reported pain and phys-
ical function are reported, we will chose the highest in 
the hierarchy of outcome measures, as recommended 
by the Cochrane Musculoskeletal Review Group.41 For 
pain these are: (1) pain overall; (2) pain on walking; 
(3) Western Ontario and McMaster Universities Osteo-
arthritis Index (WOMAC) pain subscale; (4) pain on 
activities other than walking; (5) WOMAC global scale; 
(6) Lequesne osteoarthritis index global score; (7) other 
algofunctional scale; (8) patient’s global assessment; (9) 
physician’s global assessment (10) other outcome and 
(11) no continuous outcome reported. For physical func-
tion, these are: (1) global disability score; (2) walking 
disability; (3) WOMAC disability subscore; (4) composite 
disability scores other than WOMAC; (5) disability other 
than walking; (6) WOMAC global scale; (7) Lequesne 
osteoarthritis index global score; (8) other algofunc-
tional scale. Additionally, strength of hip and lower limb 
musculature, range of movement (total range of motion, 
maximal flexion, maximal extension and extension 
deficit), and proprioception measures will be obtained 
during and directly postintervention.
Data quality assurance
We will evaluate the IPD from each trial to ensure the 
ranges of included variables are reasonable, and missing 
data will be checked against the original trial report. We 
will attempt to re-produce the results included in each 
initial trial publication, including baseline characteristics 
and self-reported pain and physical function at a time 
point nearest to 12 weeks, 6 months and 1 year postran-
domisation. Discrepancies or missing information will be 
discussed and clarified with original trial authors. Where 
discrepancies cannot be explained the trial data will be 
excluded from the analysis. Individual trial datasets will 
be combined to form a new master dataset with a variable 
added to indicate the original trial.
Assessment of risk of bias
We will use the Cochrane collaboration’s tool for assessing 
risk of bias, based on publications of the included trials.42 
Two researchers will independently grade risk of bias 
(unclear, high or low risk of bias) based on sequence 
generation, allocation concealment, blinding of outcome 
assessor, incomplete outcome data and selective outcome 
reporting. Trial design, conduct and analysis methods will 
be clarified with principal investigators. Additionally, IPD 
will be directly checked for key potential biases, including 
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whether baseline participant characteristics are balanced 
by arm. It will also be checked to ensure that data on all or 
as many randomised participants as possible are included, 
and any additional relevant outcome data from trials will 
be obtained.
Part 3: statistical analyses
We will describe trial-level and participant-level char-
acteristics (for baseline variables and outcomes) of 
included studies and examine if RCTs for which IPD are 
obtained are representative of the full set of existing RCTs 
by comparing key study characteristics, for example, 
country of origin and sample size. All meta-analyses, 
apart from the mediation analyses (objective 6 below), 
will use a two-stage approach, where each trial is anal-
ysed separately in the first stage (which accounts for 
clustering of participants within trials) to produce 
effect estimates of interest, which are then synthesised 
in the second stage to produce summary meta-analysis 
results based on a random effects model (to account 
for between-trial heterogeneity).26 Analyses will be on 
an intention-to-treat principle and all summary esti-
mates will be reported with 95% CI and P values, with 
approaches such as Hartung-Knapp used to account for 
uncertainty of variance estimates.43 44 Under a ‘missing-
at-random’ assumption, individuals with partially missing 
outcome data will be included in analyses without impu-
tation using a longitudinal data meta-analysis framework. 
If there is a considerable amount of missing baseline data 
(>5% of patients have one or more missing values) for 
particular variables of interest (such as potential individ-
ual-level effect moderators) this will be handled using 
within-study multiple imputation45 and Rubin’s rule to 
estimate effects from imputed datasets.46 All analyses will 
be carried out using Stata 14.147 or SAS 9.3.48
Objective 1
For the meta-analysis to estimate an overall intervention 
effect (at 12 weeks, 6 months and 1 year) for self-reported 
pain and physical function, all available comparisons 
will be grouped into any exercise intervention versus a 
non-exercise control. Most outcomes will be continuous, 
so linear regression models will be fitted in the first stage. 
Longitudinal models will be used to account for the 
correlation between outcome values at the multiple time-
points.49 For each trial, the model will include baseline 
pain/physical function, treatment, time and treatment by 
time interaction terms. The second stage requires a multi-
variate meta-analysis framework, which jointly syntheses 
the treatment effect estimates from the multiple time-
points across trials.50 Given the likely heterogeneity in 
the intervention effects across trials (eg, due to variability 
in patient characteristics), we will assume a multivar-
iate random-effects meta-analysis model to estimate the 
summary results of interest using restricted maximum 
likelihood estimation. Heterogeneity in treatment effects 
across trials will be summarised by the estimated between-
trial variance (τ2) and multivariate I2 statistics.
Objective 2
To determine which characteristics of exercise are associ-
ated with differences in overall effects, the meta-analysis 
approach in objective 1 will be repeated for particular 
subgroups of exercise interventions, including types, 
intensities, duration, setting or deliverer of exercise. 
To formally evaluate (although indirect) differences 
between exercise subgroups, meta-regression will be 
used. Trials comparing two different forms of exercise 
interventions will also be summarised, as these give direct 
(within-trial) information, which is preferable to indirect 
information. As appropriate, a sensitivity analysis will be 
performed to include direct and indirect evidence in one 
large (network) meta-analysis model.
Objectives 3 and 4
The IPD will be further analysed to examine treatment 
effect modification at the patient level, where individual 
patient characteristics are associated with differences in 
response to exercise. The models fitted in each trial will 
additionally include interaction terms between the inter-
vention and patient-level covariates of interest to test 
effect modification. The interaction effect estimates at 
each time-point will then be pooled across trials using a 
multivariate random-effects meta-analysis. Covariates will 
be mean centred to aid the translation of results. Analyses 
of different exercise interventions (objective 4) will also 
be extended to examine treatment–covariate interactions 
in the same way, and identify subgroups of individuals 
likely to benefit most from specific types, intensities, dura-
tion, setting and deliverer of exercise.
Objective 5
The analyses described for objectives 1–4 will be repeated 
in subgroups of people with only knee OA and only hip 
OA to examine whether the effect estimates differ by joint 
site.
Objective 6
As depicted in figure 1A, in a mediation analysis an expo-
sure can affect the outcome either through the mediator 
(E→M→O) or through other pathways (E→O). Using the 
counterfactual approach,51 the total effect of the exposure 
(exercise therapy) on the outcome (pain/physical func-
tion) through both pathways is determined. This effect 
can be decomposed into two components: the direct effect 
and the indirect effect. The direct effect refers to the causal 
pathway by which exercise therapy has an effect on pain/
physical function not through the mediator. The indirect 
effect refers to the effect of exercise therapy that operates 
solely through the mediator under investigation. The 
counterfactual approach also allows for multiple media-
tors (figure 1B).51 Given the fact that in this approach the 
total effect can be decomposed into the direct and indirect 
effects, the percentage mediated by the mediator(s) can be 
calculated as an estimation of their importance.
In an one-stage approach, first the effect of the inter-
vention (a) on the outcome (Y) will be determined, 
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controlling for the mediator (m) under investigation and 
potential mediator-outcome confounders (c), using this 
model:
 E[Y|a,m, c] = θ0 + θ1a + θ2m + θ3am + θ4c 
Next, the effect of the intervention on the mediator is 
determined, using this model:
 E[M|a, c] = β0 + β1a + β2c 
A single covariate will be added to both regression 
models to indicate each study, in order to adjust for 
possible residual confounding by study differences. Using 
these models, where θi and βi are the regression coeffi-
cients, the natural direct effect (NDE) and natural indi-
rect effect (NIE) are defined as:
 NDE = {θ1 + θ3(β0 + β1a + β2c)} 
NIE = (θ2β1 + θ3β1a) and the total effect (TE) is equal 
to the sum of NDE and NIE.49 Hence, the percentage 
mediated will be calculated by dividing NIE by TE and 
multiply this by 100%.
For knee OA, the mediating effect of upper leg muscle 
strength, extension deficits and proprioception will 
initially be analysed separately, using all data available for 
the IPD data meta-analysis. The effect of each potential 
mediator will then be evaluated adjusting for the other 
mediators in a multi-moderator model (figure 1B). In the 
latter, a separate linear regression model will be calculated 
for each mediator51 and the NIE, hence the percentage 
mediated, of each mediator can be calculated.
For hip OA, only the effect of muscle strength will 
be evaluated since this was the only factor indicated as 
a potential mediator in a systematic review.26 In all anal-
yses, the mediator will be defined as the absolute change 
from preintervention to postintervention. Therefore, 
the outcome measures that will be used will be those 
measured as close as possible to the end of the interven-
tion period and to the measurement of the mediator(s) 
under investigation. All analyses will be run with and 
without stratification for type of exercise intervention.
Sensitivity analysis: investigation of risk of bias
Effect estimates will be explored using data only from 
trials deemed to be at low risk of bias from: random 
sequence generation; allocation concealment; blinded 
outcome assessment; incomplete outcome data; and trials 
deemed to be at low risk of bias across all domains.
Unavailable IPD
For trials where IPD were not obtained, we will seek to 
extract suitable aggregate data from their trial publica-
tions and combine these with the IPD trials using suitable 
statistical methods, to determine whether conclusions 
remain the same.27 This is only likely to be possible when 
examining overall effects, as subgroup differences (inter-
actions) are rarely reported.
Investigation of small study effects
In meta-analyses of 10 trials or more, contour-enhanced 
funnel plots and tests for asymmetry will be used to inves-
tigate small trial effects and the potential for publication 
bias. Restriction to 10 trials is because there is low power 
to detect small trial effects with few studies.52
EthICs And dIssEMInAtIOn
Research ethical or governance approval is exempt for 
this study as no new data are being collected.53 54 Find-
ings will be presented at national (UK) and international 
conferences and submitted for publication in high-
quality peer review journals. We will more broadly dissem-
inate the results to physiotherapists, GPs, practice nurses, 
orthopaedic surgeons, patients and the general public 
both nationally and internationally by posting summaries 
on university websites, placing summaries in local health-
care settings and sending a summary to relevant groups 
and organisations for wider dissemination, for example, 
Osteoarthritis Research Society International, the Euro-
pean League Against Rheumatism, the American College 
of Rheumatology and Arthritis Research UK. Our PPIE 
working group will assist in developing plain English 
summaries and will jointly write articles that will be sent to 
newspapers, news websites, radio and other news media 
for wider dissemination.
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